Your session is about to expire
← Back to Search
Batiraxcept + Durvalumab for Ovarian Cancer
Study Summary
This trial is testing the side effects and best dose of AVB-S6-500 in combination with durvalumab for patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have or had an autoimmune or inflammatory disorder.You have a disease that can be measured using specific guidelines.I have moderate to severe nerve damage.I don't have lasting side effects from cancer treatment worse than grade 2.I am post-menopausal or not currently pregnant.Your heart's electrical activity, called the QT interval, is longer than 470 milliseconds when adjusted for your heart rate.I do not have any unmanaged ongoing illnesses.I have cancer that has spread to my brain or spinal cord.My cancer got worse or came back within 6 months after platinum-based treatment.You have a high number of a type of white blood cell called neutrophils.I have an ongoing blockage in my intestines.I received my last cancer treatment less than 28 days ago.I am not currently on any cancer treatments like chemotherapy or hormone therapy.Your bilirubin level in the blood is not higher than 1.5 times the normal limit.I have not taken immunosuppressive drugs in the last 14 days.I do not have active infections like TB, hepatitis B, hepatitis C, or HIV.Your platelet count is at least 100 billion per liter.I have had another type of cancer.I have not received a live vaccine in the last 30 days.I am willing and able to follow the study's requirements, including treatments and visits.I have side effects from past treatments that won't get worse with durvalumab.I am not pregnant or breastfeeding and agree to use birth control during and up to 180 days after treatment.I am fully active or restricted in physically strenuous activity but can do light work.You are expected to live for at least 12 more weeks.Your hemoglobin level is 9.0 grams per deciliter or higher.I have not had major surgery in the last 28 days.I have no standard treatment options left for my condition.You have received an organ transplant from another person.My cancer is a recurrent high-grade type in the ovary, peritoneum, or fallopian tube.My body weight is over 30 kg.My liver function tests are within normal limits, or slightly above if I have liver metastases.Your kidneys are working well and can filter out waste products.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Arm I (batiraxcept, durvalumab)
- Group 2: Arm II (durvalumab, batiraxcept)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many participants have consented to this clinical trial?
"At present, this medical trial is not presently enrolling patients. The clinical trial was first listed on October 11th 2019 and the latest update occurred on December 8th 2022. There are currently 3693 studies recruiting for recurrent ovarian carcinoma, as well as 334 trials actively seeking participants to test out Batiraxcept."
Have there been prior investigations utilizing Batiraxcept?
"Currently, there are 334 active clinical trials with 51 of those in the final Phase 3 stage. Although most studies for Batiraxcept originate from Nashville, Tennessee, this drug is being explored at 12994 different sites worldwide."
How has Batiraxcept been implemented as a treatment option?
"Batiraxcept is a common treatment for stage 3 unresectable non-small cell lung cancer. Additionally, it has been employed to treat metastatic ureteral carcinoma and advanced directives."
Are there any openings to participate in this experiment?
"Clinicaltrials.gov attests that the posted trial, which was established in October 2019 and updated last December, is not accepting applicants presently. However, there are still plenty of other medical trials available with 4027 being open for recruitment."
Share this study with friends
Copy Link
Messenger